Form 4: Medicinova Director Carolyn Beaver Granted 20,000 Stock Options

Carolyn Beaver, a Director at Medicinova Inc. (MNOV), was granted 20,000 stock options with an exercise price of $1.26, vesting in four equal installments through June 2026.

Summary

• Carolyn Beaver, a Director of Medicinova Inc. (MNOV), was granted 20,000 stock options.
• The stock options have an exercise price of $1.26 per share.
• The options will vest in four equal installments of 5,000 shares each.
• Vesting dates are September 30, 2025, December 31, 2025, March 31, 2026, and June 30, 2026.
• Vesting is subject to Carolyn Beaver's continued service with Medicinova Inc.
• The expiration date for these stock options is June 16, 2035.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as the stock option grant aligns the director's interests with shareholder value, which is generally viewed favorably. However, it is a routine compensation event and does not indicate significant operational or financial news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• This represents a form of compensation for the director's service to the company.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's financial performance or strategic outlook, beyond the vesting schedule of the granted options.

Industry Context

The grant of stock options to directors is a common practice across various industries, including biotechnology and pharmaceuticals, as a means of executive compensation and to align leadership interests with shareholder value. This filing is a routine disclosure of such an event.

Related Party Transactions

• The grant of stock options to Carolyn Beaver, a Director of Medicinova Inc., constitutes a related party transaction as she is an insider of the company.

Stakeholder Impact

• Shareholders: The grant aims to align the director's long-term interests with shareholder value, potentially leading to improved governance and performance.
• Director (Carolyn Beaver): Receives equity compensation, incentivizing her continued service and performance.

Next Steps

• The stock options will vest in four equal installments on September 30, 2025, December 31, 2025, March 31, 2026, and June 30, 2026, contingent on continued service.

Key Dates

Keywords

Medicinova, MNOV, Stock Option, Form 4, Beneficial Ownership, Director Compensation, Equity Grant, Insider Trading